• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奔向目标:欧洲心脏病学会/欧洲呼吸学会肺动脉高压目标导向性风险降低策略的另一种靶心参数显示

Dart to the target: an alternative bull's eye parametric display for European Society of Cardiology / European Respiratory Society goal-orientated risk reduction strategy in pulmonary arterial hypertension.

作者信息

Kaymaz Cihangir, Akbal Ozgur Yasar, Hakgor Aykun, Tokgoz Hacer Ceren, Tanyeri Seda

机构信息

University of Health Sciences, Kosuyolu Heart Education and Research Hospital Cevizli Mah., İstanbul, Turkey.

出版信息

Pulm Circ. 2018 Jul-Sep;8(3):2045894018780522. doi: 10.1177/2045894018780522. Epub 2018 May 16.

DOI:10.1177/2045894018780522
PMID:29767575
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6055270/
Abstract

Despite the significant mortality and mobidity benefits being obtained with the targeted therapies in patients with pulmonary arterial hypertension (PAH), mid- to long-term survival of patients with this disease has remained unsatisfactory. For earlier and reliable risk stratification in PAH and tailoring the dynamic management strategies, various risk assessment models have been developed. Currently available risk reduction strategy recommended by the European Society of Cardiology (ESC)/European Respiratory Society (ERS) 2015 Pulmonary Hypertension Guidelines has been utilized in three recent registries. In this review, we evaluated the risk prediction models and management algorithms in this setting and propose an alternative parametric display, a bull's eye, dart table scheme for ESC/ERS goal-orientated risk reduction strategy in patients with PAH.

摘要

尽管靶向治疗给肺动脉高压(PAH)患者带来了显著的死亡率和发病率改善,但该疾病患者的中长期生存率仍不尽人意。为了对PAH进行早期且可靠的风险分层并制定动态管理策略,人们开发了各种风险评估模型。欧洲心脏病学会(ESC)/欧洲呼吸学会(ERS)2015年肺动脉高压指南推荐的现有风险降低策略已在最近的三个登记研究中得到应用。在本综述中,我们评估了这种情况下的风险预测模型和管理算法,并提出了一种替代的参数显示方法,即靶心、飞镖表方案,用于PAH患者ESC/ERS目标导向的风险降低策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6255/6055270/d020f1c624bd/10.1177_2045894018780522-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6255/6055270/809c35f5fb08/10.1177_2045894018780522-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6255/6055270/d020f1c624bd/10.1177_2045894018780522-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6255/6055270/809c35f5fb08/10.1177_2045894018780522-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6255/6055270/d020f1c624bd/10.1177_2045894018780522-fig2.jpg

相似文献

1
Dart to the target: an alternative bull's eye parametric display for European Society of Cardiology / European Respiratory Society goal-orientated risk reduction strategy in pulmonary arterial hypertension.奔向目标:欧洲心脏病学会/欧洲呼吸学会肺动脉高压目标导向性风险降低策略的另一种靶心参数显示
Pulm Circ. 2018 Jul-Sep;8(3):2045894018780522. doi: 10.1177/2045894018780522. Epub 2018 May 16.
2
Evaluation of the European Society of Cardiology/European Respiratory Society derived three- and four-strata risk stratification models in pulmonary arterial hypertension: introducing an internet-based risk stratification calculator.欧洲心脏病学会/欧洲呼吸学会推导的肺动脉高压三阶层和四阶层风险分层模型评估:引入基于互联网的风险分层计算器
Eur Heart J Open. 2023 Feb 21;3(2):oead012. doi: 10.1093/ehjopen/oead012. eCollection 2023 Mar.
3
Risk stratification in pulmonary arterial hypertension.肺动脉高压的风险分层。
Curr Opin Pulm Med. 2018 Sep;24(5):407-415. doi: 10.1097/MCP.0000000000000510.
4
Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era.加拿大肺动脉高压死亡率趋势:按 ESC/ERS 指南时代划分的生存时间分析。
Eur Respir J. 2022 Jun 2;59(6). doi: 10.1183/13993003.01552-2021. Print 2022 Jun.
5
Risk stratification in adult and pediatric pulmonary arterial hypertension: A systematic review.成人及儿童肺动脉高压的风险分层:一项系统综述。
Front Cardiovasc Med. 2022 Nov 10;9:1035453. doi: 10.3389/fcvm.2022.1035453. eCollection 2022.
6
European Society of Cardiology quality indicators for the care and outcomes of adults with pulmonary arterial hypertension. Developed in collaboration with the Heart Failure Association of the European Society of Cardiology.欧洲心脏病学会肺动脉高压成年患者护理及预后质量指标。与欧洲心脏病学会心力衰竭协会合作制定。
Eur J Heart Fail. 2023 Apr;25(4):469-477. doi: 10.1002/ejhf.2830. Epub 2023 Apr 4.
7
Risk stratification strategy and assessment of disease progression in patients with pulmonary arterial hypertension: Updated Recommendations from the Cologne Consensus Conference 2018.肺动脉高压患者的风险分层策略和疾病进展评估:2018 年科隆共识会议更新的建议。
Int J Cardiol. 2018 Dec 1;272S:20-29. doi: 10.1016/j.ijcard.2018.08.084. Epub 2018 Sep 13.
8
Assessment of Risk of Disease Progression in Pulmonary Arterial Hypertension: Insights from an International Survey of Clinical Practice.肺动脉高压疾病进展风险评估:国际临床实践调查的见解。
Adv Ther. 2019 Sep;36(9):2351-2363. doi: 10.1007/s12325-019-01030-4. Epub 2019 Jul 16.
9
Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies.预测肺动脉高压患者的生存情况:REVEAL 风险评分计算器 2.0 与 ESC/ERS 风险评估策略的比较。
Chest. 2019 Aug;156(2):323-337. doi: 10.1016/j.chest.2019.02.004. Epub 2019 Feb 14.
10
Incorporation of renal function in mortality risk assessment for pulmonary arterial hypertension.评估肺动脉高压患者死亡率时纳入肾功能。
J Heart Lung Transplant. 2020 Jul;39(7):675-685. doi: 10.1016/j.healun.2020.03.026. Epub 2020 Apr 5.

引用本文的文献

1
The Consistent Effectiveness and Safety of Macitentan Therapies Across Idiopathic and Congenital Heart Disease-Associated PulmonaryArterial Hypertension: A Single-Center Experience.马西替坦治疗特发性和先天性心脏病相关肺动脉高压的一致性疗效和安全性:单中心经验。
Anatol J Cardiol. 2022 Oct;26(10):778-787. doi: 10.5152/AnatolJCardiol.2022.1889.
2
Impaired endothelium-dependent and endothelium-independent systemic vasodilatory reserve in pulmonary hypertension regardless the clinical group: A generalized dysfunction beyond the pulmonary arteries?无论临床分组如何,肺动脉高压患者均存在受损的内皮依赖性和非内皮依赖性全身血管舒张储备:肺动脉以外的普遍功能障碍?
Anatol J Cardiol. 2021 Oct;25(10):733-740. doi: 10.5152/AnatolJCardiol.2021.474.
3

本文引用的文献

1
Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension.年龄和合并症对特发性肺动脉高压危险分层的影响。
Eur Respir J. 2018 May 3;51(5). doi: 10.1183/13993003.02310-2017. Print 2018 May.
2
Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL Registry.基线和连续脑利钠肽水平可预测肺动脉高压患者 5 年总生存率:来自 REVEAL 登记的数据。
Chest. 2018 Jul;154(1):126-135. doi: 10.1016/j.chest.2018.01.009. Epub 2018 Jan 31.
3
The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?
Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey.肺动脉高压患者的风险评估与生存情况:土耳其的多中心经验
Anatol J Cardiol. 2019 Jun;21(6):322-330. doi: 10.14744/AnatolJCardiol.2019.53498.
肺动脉高压的低风险特征。是时候向以目标为导向的临床试验终点进行范式转变了吗?
Am J Respir Crit Care Med. 2018 Apr 1;197(7):860-868. doi: 10.1164/rccm.201709-1840PP.
4
REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival.REVEAL 风险评分在 PATENT-2 中接受 riociguat 治疗的患者中的应用:风险评分变化对生存的影响。
J Heart Lung Transplant. 2018 Apr;37(4):513-519. doi: 10.1016/j.healun.2017.11.006. Epub 2017 Nov 11.
5
Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis.肾功能下降对肺动脉高压结局的影响:一项 REVEAL 登记分析。
J Heart Lung Transplant. 2018 Jun;37(6):696-705. doi: 10.1016/j.healun.2017.10.028. Epub 2017 Nov 6.
6
Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension.初始治疗后随访血流动力学变量对肺动脉高压的预后价值。
Circulation. 2018 Feb 13;137(7):693-704. doi: 10.1161/CIRCULATIONAHA.117.029254. Epub 2017 Oct 25.
7
Assessing risk in pulmonary arterial hypertension: what we know, what we don't.评估肺动脉高压的风险:我们已知的与未知的。
Eur Respir J. 2017 Aug 3;50(2). doi: 10.1183/13993003.01353-2017. Print 2017 Aug.
8
Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension.肺动脉高压的风险评估、预后和指南实施。
Eur Respir J. 2017 Aug 3;50(2). doi: 10.1183/13993003.00889-2017. Print 2017 Aug.
9
Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model.肺动脉高压死亡率:2015 年欧洲肺动脉高压指南风险分层模型预测。
Eur Respir J. 2017 Aug 3;50(2). doi: 10.1183/13993003.00740-2017. Print 2017 Aug.
10
Validation of a risk assessment instrument for pulmonary arterial hypertension.一种用于肺动脉高压的风险评估工具的验证
Eur Heart J. 2018 Dec 14;39(47):4182-4185. doi: 10.1093/eurheartj/ehx301.